Skip to Content

Ditropan Side Effects

Generic Name: oxybutynin

Note: This page contains information about the side effects of oxybutynin. Some of the dosage forms included on this document may not apply to the brand name Ditropan.

For the Consumer

Applies to oxybutynin: oral syrup, oral tablet, oral tablet extended release

In addition to its needed effects, some unwanted effects may be caused by oxybutynin (the active ingredient contained in Ditropan). In the event that any of these side effects do occur, they may require medical attention.

Severity: Major

You should check with your doctor immediately if any of these side effects occur when taking oxybutynin:

  • Eye pain
  • skin rash or hives

If any of the following symptoms of overdose occur while taking oxybutynin, get emergency help immediately:

Symptoms of overdose:
  • Clumsiness or unsteadiness
  • confusion
  • convulsions
  • dizziness
  • drowsiness (severe)
  • fainting
  • fast, slow, or irregular heartbeat
  • fever
  • flushing or redness of the face
  • hallucinations (seeing, hearing, or feeling things that are not there)
  • troubled breathing
  • unusual excitement, nervousness, restlessness, or irritability

Severity: Minor

Some of the side effects that can occur with oxybutynin may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

More common:
  • Acid or sour stomach
  • belching
  • decreased sweating
  • diarrhea
  • difficulty having a bowel movement (stool)
  • drowsiness
  • dryness of the eyes, mouth, nose, or throat
  • heartburn
  • indigestion
  • runny nose
  • stomach discomfort, upset, or pain
Less common or rare:
  • Blurred vision
  • decreased flow of breast milk
  • decreased sexual ability
  • difficulty in swallowing
  • feeling of warmth or heat
  • headache
  • increased sensitivity of the eyes to light
  • nausea or vomiting
  • trouble with sleeping
  • unusual tiredness or weakness
Incidence not known: - Observed during clinical practice with oxybutynin; estimates of frequency cannot be determined
  • Bloating or swelling of the face, arms, hands, lower legs, or feet
  • decreased interest in sexual intercourse
  • inability to have or keep an erection
  • loss in sexual ability, desire, drive, or performance
  • rapid weight gain
  • tingling of the hands or feet
  • unusual weight gain or loss

For Healthcare Professionals

Applies to oxybutynin: oral syrup, oral tablet, oral tablet extended release, transdermal film extended release, transdermal gel

Nervous system

Very common (10% or more): Dizziness, somnolence
Common (1% to 10%): Headache, confusion, insomnia, nervousness, convulsions, dysgeusia
Frequency not reported: Heat stroke, paralysis, coma, CNS excitation[Ref]


Reports of moderate to severe dry mouth was significantly lower in the group of people taking oxybutynin (the active ingredient contained in Ditropan) extended-release form in a study, at the same daily dose, comparing it to oxybutynin immediate-release. The reported incidence of dry mouth with the extended-release formulation is lower with the use of lower daily doses.

Dry mouth has been mentioned as the primary reason given by patients for discontinuation of therapy.[Ref]

Very common (10% or more): Dry mouth, constipation, nausea
Common (1% to 10%): Dyspepsia, diarrhea, flatulence, vomiting, decreased GI motility, loose stools, aptyalism, eructation, tongue coated, gastroesophageal reflux, abdominal pain, taste perversion
Uncommon (0.1% to 1%): Dysphagia, frequent bowel movements
Frequency not reported: Taste perversion[Ref]


Common (1% to 10%): Palpitations, peripheral edema, tachycardia, vasodilation, hypertension, chest pain
Uncommon (0.1% to 1%): Hot flush
Rare (less than 0.1%): Chest discomfort
Frequency not reported: Hypotension
Postmarketing reports: QT interval prolongation, arrhythmia, flushing[Ref]


Very common (10% or more): Pruritus with transdermal system
Common (1% to 10%): Decreased sweating, dry skin, rash, pruritus
Frequency not reported: Application site vesicles, macules, burning, rash, and erythema with transdermal system.[Ref]


Very common (10% or more): Impaired urination, urinary tract infections
Common (1% to 10%): Increased post void retention, urinary retention, impotence, urinary hesitancy, dysuria, pollakiuria
Frequency not reported: Dysuria, cystitis, aggravation of symptoms of prostatic hypertrophy[Ref]


Postmarketing reports: Suppression of lactation[Ref]


Uncommon (0.1% to 1%): Anorexia, fluid retention, increased blood glucose
Frequency not reported: Dehydration, aggravation of hyperthyroidism symptoms[Ref]


Very common (10% or more): Blurred vision
Common (1% to 10%): Cycloplegia, dry eyes, mydriasis, keratoconjunctivitis sicca, eye irritation
Frequency not reported: Acute angle closure glaucoma, amblyopia, decreased lacrimation
Postmarketing reports: Glaucoma[Ref]


Common (1% to 10%): Rhinitis, bronchitis, nasal dryness, oropharyngeal pain, cough, dry throat, sinus/nasal congestion, hoarseness, asthma, dry nasal and sinus mucous membranes
Uncommon (0.1% to 1%): Dysphonia
Frequency not reported: Upper respiratory tract infections, sinusitis, bronchitis, pharyngitis, respiratory failure[Ref]


Common (1% to 10%): Asthenia, back pain, arthralgia, pain in extremity, flank pain
Frequency not reported: Arthritis[Ref]


Common (1% to 10%): Depression, nervousness, insomnia, confusional state
Frequency not reported: Cognitive and mental status changes in elderly patients
Postmarketing reports: Hallucinations, psychotic disorder, agitation, memory impairment[Ref]


Common (1% to 10%): Fatigue, fungal infection
Uncommon (0.1% to 1%): Thirst
Frequency not reported: Accidental injury, flu syndrome, flushing, fever
Postmarketing reports: Falls


Frequency not reported: Angioedema with airway obstruction, urticaria, and face edema and rare anaphylactic reactions[Ref]


1. Vaidyanathan S, Krishnan KR, Soni BM, Fraser MH "Exaggerated neurological side-effects of oral and intravesical oxybutynin in a patient with multiple sclerosis [letter." Spinal Cord 35 (1997): 190-1

2. Primus G, Pummer K "Oxybutynin hydrochloride in the management of detrusor instability." Int Urol Nephrol 22 (1990): 243-8

3. Moore KH, Hay DM, Imrie AE, Watson A, Goldstein M "Oxybutynin hydrochloride (3 mg) in the treatment of women with idiopathic detrusor instability." Br J Urol 66 (1990): 479-85

4. Pietzko A, Dimpfel W, Schwantes U, Topfmeier P "Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers." Eur J Clin Pharmacol 47 (1994): 337-43

5. Iselin CE, Schmidlin F, Borst F, Rohner S, Graber P "Oxybutynin in the treatment of early detrusor instability after transurethral resection of the prostate." Br J Urol 79 (1997): 915-9

6. Donnellan CA, Fook L, McDonald P, Playfer JR "Oxybutynin and cognitive dysfunction [see comments]." BMJ 315 (1997): 1363-4

7. Adubofour KO, Kajiwara GT, Goldberg CM, King-Angell JL "Oxybutynin-induced heatstroke in an elderly patient." Ann Pharmacother 30 (1996): 144-7

8. "Product Information. Ditropan (oxybutynin)." Hoechst Marion-Roussel Inc, Kansas City, MO.

9. Gleason DM, Susset J, White C, Munoz DR, Sand PK "Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence." Urology 54 (1999): 420-3

10. Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D'Angelo K "Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride." J Am Geriatr Soc 46 (1998): 8-13

11. Tapp AJ, Cardozo LD, Versi E, Cooper D "The treatment of detrusor instability in post-menopausal women with oxybutynin chloride: a double blind placebo controlled study [se comments." Br J Obstet Gynaecol 97 (1990): 521-6

12. Brooks ME, Braf ZF "Oxybutynin Chloride (Ditrophan)--clinical uses and limitations." Paraplegia 18 (1980): 64-8

13. Nagy F, Hamvas A, Frang D "Idiopathic bladder hyperactivity treated with Ditropan (oxybutynin chloride)." Int Urol Nephrol 22 (1990): 519-24

14. Lee M, Sharifi R "Oxybutynin-induced reflux esophagitis." DICP 24 (1990): 583-5

15. Versi E, Appell R, Mobley D, Patton W, Saltzstein D "Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence." Obstet Gynecol 95 (2000): 718-21

16. Hock CW "Clinical evaluation of oxybutynin chloride." Curr Ther Res Clin Exp 9 (1967): 437-40

17. Abrams P, Freeman R, Anderstrom C, Mattiasson A "Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder." Br J Urol 81 (1998): 801-10

18. Moisey CU, Stephenson TP, Brendler CB "The urodynamic and subjective results of treatment of detrusor instability with oxybutynin chloride." Br J Urol 52 (1980): 472-5

19. "Product Information. Oxytrol (oxybutynin)." Watson Laboratories Inc, Corona, CA.

20. Thuroff JW, Bunke B, Ebner A, Faber P, de Geeter P, Hannappel J, Heidler H, Madersbacher H, Melchior H, Schafer W, et al "Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detruso hyperactivity: oxybutynin versus propantheline versus placebo." J Urol 145 (1991): 813-6;disc. 816-7

21. Hussain RM, Hartigan-Go K, Thomas SH, Ford GA "Effect of oxybutynin on the QTc interval in elderly patients with urinary incontinence." Br J Clin Pharmacol 41 (1996): 73-5

22. Sung VC, Corridan PG "Acute-angle closure glaucoma as a side-effect of oxybutynin." Br J Urol 81 (1998): 634-5

23. Paulson DF "Oxybutynin chloride in the management of idiopathic detrusor instability." South Med J 72 (1979): 374-5

Not all side effects for Ditropan may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.